Bristol Myers Squibb

The drug RYZ101 met the primary endpoint in a Phase-3 study and improved progression-free survival, supporting the focus on precision oncology. Bristol Myers Squibb sees the results as validation of its strategy to generate additional growth through acquisitions. The company is in a consolidation phase and expects 2026 revenue of $49–50 billion while aiming to offset revenue losses from expiring patents. » Más en finanzen.net

Bristol-Myers Squibb shares rose to a 52-week high of $68.10 and have gained about 43% over the past year. The stock trades at a P/E ratio of 14.6 but is rated by InvestingPro as overvalued relative to fair value; the company has paid a dividend for 56 years, with a yield of 3.82%. Additionally, the company reported an accelerated approval for Zenbexus, Guggenheim confirmed a "Buy" with a $75.00 target, and Bristol-Myers plans an approximately $2.3 billion production facility in Houston; market rumours of possible takeover interest from AstraZeneca remain unconfirmed. » Más en de.investing.com

The FDA granted Bristol Myers Squibb accelerated approval for Zenbexus (iberdomid) in combination with daratumumab (with hyaluronidase) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy. Zenbexus is the first approved cereblon‑modulating protein degrader; the decision is based on the Phase 3 EXCALIBER‑RRMM study, in which 41% of patients treated with the combination achieved a complete remission without minimal residual disease versus 21% in the control arm (median follow‑up 16 months). The approval is conditional on confirmatory trials that will evaluate, among other endpoints, progression‑free survival. Key safety information includes embryofetal toxicity, thromboembolic risks, a REMS program, a high rate of serious adverse events (58.3%) and pronounced neutropenia (90.2%); 4.9% of patients experienced fatal adverse events. Bristol Myers Squibb is also developing mezigdomid, with an FDA decision targeted for May 13, 2027. » Más en de.investing.com